Prevalence of Nonsteroidal Antiinflammatory Drugs Prescribed for Osteoarthritis: A Systematic Review and <scp>Meta‐Analysis</scp> of Observational Studies

Yang, Zhen; Mathieson, Stephanie; Kobayashi, Sarah; Shaheed, Christina Abdel; Nogueira, Leandro Alberto Calazans; Simić, Milena; Machado, Gustavo C; McLachlan, Andrew J.

doi:10.1002/acr.25157

Cited by 6 publications

(2 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Следует отметить, что на протяжении последних лет имеет место тенденция к снижению частоты применения НПВП при лечении пациентов с некоторыми скелетно-мышечными БС, в частности обусловленными ОА. Так, проанализированы результаты 51 исследования, результаты опубликованы в период с 1989 по 2022 г.; в исследованиях в общей сложности приняли участие 6 494 509 пациентов, средний возраст участников составил 64,7 года (95% доверительный интервал -ДИ 62,4-67,0) [29]. Основная часть исследований проведена в странах Европы и Центральной Азии (23 исследования) и Северной Америки (12 исследований).…”

Section: основные направления лечения пациентов с даunclassified

The choice of pathogenetic therapy for a patient with dorsalgia: A review

Kamchatnov,

Cheremin,

Skipetrova

et al. 2024

Consilium Medicum

View full text Add to dashboard Cite

Musculoskeletal pain syndromes are one of the common causes of temporary disability associated with a decrease in the quality of life of patients. Dorsalgia (DA) is the most common form of these syndromes. Currently, osteoarthritis of the facet joints has been replaced as one of the main mechanisms for the occurrence of DA. The article discusses the main causes of DA development, important inflammatory processes in its symptoms. The issues of treatment of patients with DA are discussed. Information about the efficacy and safety of the use of Nise® (nimesulide) is given.

show abstract

Section: основные направления лечения пациентов с даunclassified

The choice of pathogenetic therapy for a patient with dorsalgia: A review

Kamchatnov,

Cheremin,

Skipetrova

et al. 2024

Consilium Medicum

View full text Add to dashboard Cite

show abstract

“…Osteoarthritis (OA) is a major cause of chronic pain, affecting over 32.5 million US adults [ 1 – 3 ]. The use of non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain is common [ 4 – 8 ]. Non-steroidal anti-inflammatory drugs are effective pain relievers, acting by inhibition of cyclooxygenase (COX) enzymes and thereby blockage of prostaglandin biosynthesis.…”

Section: Introductionmentioning

confidence: 99%

Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

Ide,

Shoaibi,

Wagner

et al. 2024

Drugs Aging

View full text Add to dashboard Cite

Background Osteoarthritis (OA) is a major cause of chronic pain. Non-steroidal anti-inflammatory drugs (NSAIDs) are analgesics commonly used for musculoskeletal pain; however, NSAIDs can increase the risk of certain adverse events, such as gastrointestinal bleeding, edema, heart failure, and hypertension. Objective The objective of this study was to characterize existing comorbidities among patients with OA. For patients with OA with and without a coexisting medical condition of interest (CMCOI), we estimated the prevalence of prescribing and dispensing NSAIDs pre-OA and post-OA diagnosis. Methods Data from three large administrative claims databases were used to construct an OA retrospective cohort. Databases leveraged were IBM MarketScan Medicare Supplemental Database (MDCR), IBM MarketScan Commercial Database (CCAE), and Optum’s de-identified Clinformatics ® Data Mart Database (Optum CDM). The OA study population was defined to be those patients who had an OA diagnosis from an inpatient or outpatient visit with at least 365 days of prior observation time in the database during January 2000 through May 2021. Asthma, cardiovascular disorders, renal impairment, and gastrointestinal bleeding risks were the CMCOI of interest. Patients with OA were then classified as having or not having evidence of a CMCOI. For both groups, NSAID dispensing patterns pre-OA and post-OA diagnosis were identified. Descriptive analysis was performed within the Observational Health Data Sciences and Informatics framework. Results In each database, the proportion of the OA population with at least one CMCOI was nearly 50% or more (48.0% CCAE; 74.4% MDCR; 68.6% Optum CDM). Cardiovascular disease was the most commonly observed CMCOI in each database, and in two databases, nearly one in four patients with OA had two or more CMCOI (23.2% MDCR; 22.6% Optum CDM). Among the OA population with CMCOI, NSAID utilization post-OA diagnosis ranged from 33.0 to 46.2%. Following diagnosis of OA, an increase in the prescribing and dispensing of NSAIDs was observed in all databases, regardless of patient CMCOI presence. Conclusions This study provides real-world evidence of the pattern of prescribing and dispensing of NSAIDs among patients with OA with and without CMCOI, which indicates that at least half of patients with OA in the USA have a coexisting condition. These conditions may increase the risk of side effects commonly associated with NSAIDs. Yet, at least 32% of these patients were prescribed and dispensed NSAIDs. These data support the importance of shared decision making between healthcare professionals and patients when considering NSAIDs for the treatment of OA in patients with NSAID-relevant coexisting medical conditions. Supplementary Information The online version contains supplementary material available at 10.1007/s40266-024-01108-x.

show abstract

Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses

Cao,

Han,

et al. 2024

Drugs

View full text Add to dashboard Cite

Background and Objective Although paracetamol (acetaminophen) combined with other analgesics can reduce pain intensity in some pain conditions, its effectiveness in managing low back pain and osteoarthritis is unclear. This systematic review investigated whether paracetamol combination therapy is more effective and safer than monotherapy or placebo in low back pain and osteoarthritis. Methods Online database searches were conducted for randomised trials that evaluated paracetamol combined with another analgesic compared to a placebo or the non-paracetamol ingredient in the combination (monotherapy) in low back pain and osteoarthritis. The primary outcome was a change in pain. Secondary outcomes were (serious) adverse events, changes in disability and quality of life. Follow-up was immediate (≤ 2 weeks), short (> 2 weeks but ≤ 3 months), intermediate (> 3 months but < 12 months) or long term (≥ 12 months). A random-effects meta-analysis was conducted. Risk of bias was assessed using the original Cochrane tool, and quality of evidence using Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results Twenty-two studies were included. Pain was reduced with oral paracetamol plus a non-steroidal anti-inflammatory drug (NSAID) at immediate term in low back pain (paracetamol plus ibuprofen vs ibuprofen [mean difference (MD) − 6.2, 95% confidence interval (CI) −10.4 to −2.0, moderate evidence]) and in osteoarthritis (paracetamol plus aceclofenac vs aceclofenac [MD − 4.7, 95% CI − 8.3 to − 1.2, moderate certainty evidence] and paracetamol plus etodolac vs etodolac [MD − 15.1, 95% CI − 18.5 to − 11.8; moderate certainty evidence]). Paracetamol plus oral tramadol reduced pain compared with placebo at intermediate term for low back pain (MD − 11.7, 95% CI − 19.2 to − 4.3; very low certainty evidence) and osteoarthritis (MD − 6.8, 95% CI − 12.7 to −0.9; moderate certainty evidence). Disability scores improved in half the comparisons. Quality of life was infrequently measured. All paracetamol plus NSAID combinations did not increase the risk of adverse events compared to NSAID monotherapy. Conclusions Low-to-moderate quality evidence supports the oral use of some paracetamol plus NSAID combinations for short-term pain relief with no increased risk of harm for low back pain and osteoarthritis compared to its non-paracetamol monotherapy comparator.

show abstract

Prevalence of Nonsteroidal Antiinflammatory Drugs Prescribed for Osteoarthritis: A Systematic Review and Meta‐Analysis of Observational Studies

Cited by 6 publications

References 84 publications

The choice of pathogenetic therapy for a patient with dorsalgia: A review

The choice of pathogenetic therapy for a patient with dorsalgia: A review

Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses

Contact Info

Product

Resources

About